RU2316318C2 - Фармацевтическая композиция, включающая ингибитор ренина, блокатор кальциевых каналов и диуретик - Google Patents

Фармацевтическая композиция, включающая ингибитор ренина, блокатор кальциевых каналов и диуретик Download PDF

Info

Publication number
RU2316318C2
RU2316318C2 RU2004137104/15A RU2004137104A RU2316318C2 RU 2316318 C2 RU2316318 C2 RU 2316318C2 RU 2004137104/15 A RU2004137104/15 A RU 2004137104/15A RU 2004137104 A RU2004137104 A RU 2004137104A RU 2316318 C2 RU2316318 C2 RU 2316318C2
Authority
RU
Russia
Prior art keywords
disease
diabetic
aliskiren
amlodipine
pharmaceutical composition
Prior art date
Application number
RU2004137104/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2004137104A (ru
Inventor
Дейвид Луис ФЕЛДМАН (US)
Дейвид Луис ФЕЛДМАН
Ранди Ли УЭББ (US)
Ранди Ли УЭББ
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29550141&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2316318(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2004137104A publication Critical patent/RU2004137104A/ru
Application granted granted Critical
Publication of RU2316318C2 publication Critical patent/RU2316318C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
RU2004137104/15A 2002-05-17 2003-05-16 Фармацевтическая композиция, включающая ингибитор ренина, блокатор кальциевых каналов и диуретик RU2316318C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38154602P 2002-05-17 2002-05-17
US60/381,546 2002-05-17

Publications (2)

Publication Number Publication Date
RU2004137104A RU2004137104A (ru) 2005-09-10
RU2316318C2 true RU2316318C2 (ru) 2008-02-10

Family

ID=29550141

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004137104/15A RU2316318C2 (ru) 2002-05-17 2003-05-16 Фармацевтическая композиция, включающая ингибитор ренина, блокатор кальциевых каналов и диуретик

Country Status (24)

Country Link
US (3) US20050182042A1 (enExample)
EP (2) EP1507558B8 (enExample)
JP (2) JP5288678B2 (enExample)
KR (3) KR20130109244A (enExample)
CN (1) CN1655819A (enExample)
AT (1) ATE520417T1 (enExample)
AU (1) AU2003240669B2 (enExample)
BR (1) BR0310084A (enExample)
CA (1) CA2485081C (enExample)
CY (2) CY1112013T1 (enExample)
DK (1) DK1507558T3 (enExample)
EC (1) ECSP045428A (enExample)
ES (1) ES2369216T3 (enExample)
IL (1) IL164837A (enExample)
LU (1) LU92000I2 (enExample)
MX (1) MXPA04011383A (enExample)
NO (1) NO334382B1 (enExample)
NZ (1) NZ536555A (enExample)
PL (1) PL219032B1 (enExample)
PT (1) PT1507558E (enExample)
RU (1) RU2316318C2 (enExample)
SI (1) SI1507558T1 (enExample)
WO (1) WO2003097098A1 (enExample)
ZA (1) ZA200408442B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2372079C1 (ru) * 2008-05-20 2009-11-10 Илья Николаевич Медведев Способ коррекции уровня микровезикул в крови при артериальной гипертонии, дислипидемии и нарушении толерантности к глюкозе
RU2373932C1 (ru) * 2008-05-20 2009-11-27 Илья Николаевич Медведев Способ коррекции уровня микровезикул в крови при артериальной гипертонии
RU2382644C1 (ru) * 2008-11-05 2010-02-27 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" Способ коррекции гипертрофии левого желудочка у больных ибс в сочетании с гипертонической болезнью
US8613949B2 (en) 2008-09-22 2013-12-24 Novartis Ag Galenical formulations of organic compounds

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
ES2369216T3 (es) * 2002-05-17 2011-11-28 Novartis Pharma Ag Composición farmacéutica que comprende un inhibidor de renina, un bloqueador del canal de calcio y un diurético.
CN100444840C (zh) 2003-05-15 2008-12-24 罗斯坎普研究有限公司 减少淀粉样沉积、淀粉样神经毒性和小胶质增生的药物
WO2005077418A1 (en) * 2004-02-17 2005-08-25 Novartis Ag Combination of renin inhibitor and diuretics
MY148773A (en) * 2004-03-17 2013-05-31 Novartis Ag Galenic formulations of organic compounds
WO2005089731A2 (en) * 2004-03-17 2005-09-29 Novartis Ag Use of renin inhibitors in therapy
ES2257152B1 (es) * 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
AU2005247105B2 (en) * 2004-05-31 2010-11-11 Laboratorios Almirall, S.A. Combinations comprising antimuscarinic agents and corticosteroids
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
AU2006227283B2 (en) * 2005-03-22 2010-07-01 Novartis Ag Biomarkers for efficacy of aliskiren as a hypertensive agent
WO2007056324A2 (en) * 2005-11-08 2007-05-18 Novartis Ag Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
GB0612540D0 (en) * 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
EP1891937A1 (en) * 2006-08-25 2008-02-27 Novartis AG Galenic formulations of aliskiren
CA2668828A1 (en) * 2006-11-07 2008-05-29 Novartis Ag Crystalline forms of aliskiren hemifumarate
RU2456267C2 (ru) * 2006-11-09 2012-07-20 Новартис Аг Соль алискирена и оротовой кислоты
US8247370B2 (en) * 2006-12-04 2012-08-21 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
JP2010518147A (ja) * 2007-02-16 2010-05-27 ノバルティス アーゲー 有機化合物の使用
EP1972335A1 (en) * 2007-03-23 2008-09-24 Krka Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
RU2363472C2 (ru) * 2007-05-22 2009-08-10 Государственное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова Федерального агентства по здравоохранению и социальному развитию" Способ профилактики и лечения кардиоваскулярных осложнений у больных с хронической болезнью почек, находящихся на гемодиализе, имеющих анурию
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
BRPI0817516A2 (pt) 2007-10-05 2015-06-16 Alzheimer S Inst Of America Inc Método para reduzir deposição de amilóide, neurotoxicidade de amilóide e microgliose com o enantiômero de (-)-nilvadipino
EP2062874B1 (en) 2007-11-20 2014-12-17 KRKA, tovarna zdravil, d.d., Novo mesto Process and intermediates for the preparation of aliskiren
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
SI2189442T1 (sl) 2008-11-20 2015-03-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek in intermediati za pripravo aliskirena
CA2755047C (en) * 2009-03-11 2018-12-04 Promedior, Inc. Treatment methods for autoimmune disorders
PT2405928T (pt) * 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
AU2010262847B2 (en) * 2009-06-17 2016-06-02 Promedior, Inc. SAP variants and their use
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
CN102247344A (zh) * 2011-05-30 2011-11-23 北京阜康仁生物制药科技有限公司 一种新型降血压组合物
CN102552277A (zh) * 2011-12-02 2012-07-11 邬林祥 氨氯地平、阿利可仑和氢氯噻嗪复方降压药物
CN102626391B (zh) * 2012-04-19 2013-07-10 海南美兰史克制药有限公司 一种阿利克仑氢氯噻嗪药物组合物脂质体固体制剂
GB201317373D0 (en) 2013-10-01 2013-11-13 Univ Dundee Treatment and prevention of cancer
CN111789843A (zh) * 2019-04-08 2020-10-20 深圳奥萨医药有限公司 含氨氯地平、氯噻酮和阿米洛利的药物组合物
KR102414285B1 (ko) * 2020-06-02 2022-06-28 이화여자대학교 산학협력단 플루나리진 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 함유하는 골질환의 예방 또는 치료용 약학적 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5178877A (en) * 1991-01-04 1993-01-12 Abbott Laboratories Encapsulated renin inhibitor composition
US5292741A (en) * 1992-08-18 1994-03-08 Merck & Co., Inc. Macrocycles incorporating quinazolinones
US5457132A (en) * 1989-03-22 1995-10-10 Peter K. T. Pang Kit used in the treatment for hypertension using combination therapy involving exogenous calcium and calcium channel blockers
HU9700588D0 (en) * 1996-03-13 1997-05-28 Pfizer Method for improving morbidity and/or mortality

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656650A (en) * 1990-12-14 1997-08-12 Smithkline Beecham Corp. Angiotensin II receptor blocking compositions
JP3398379B2 (ja) * 1990-12-14 2003-04-21 スミスクライン・ビーチャム・コーポレイション アンジオテンシンｉｉ受容体遮断組成物
US5114925A (en) * 1991-01-22 1992-05-19 Merck & Co., Inc. Renin inhibitors containing the 2-[[(2R,3S)-3-amino-4-cyclohexyl-2-hydroxy-1-butyl]thio)alkanoyl moiety and the corresponding sulfoxide and sulfone derivatives
US5256667A (en) * 1991-09-25 1993-10-26 Merck & Co., Inc. Quinazolinones and pyridopyrimidinones
US5202322A (en) * 1991-09-25 1993-04-13 Merck & Co., Inc. Quinazolinone and pyridopyrimidine a-II antagonists
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US8168616B1 (en) * 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
CA2430924A1 (en) * 2000-12-01 2002-06-06 Novartis Ag Angiotensin receptor antagonist composition for the treatment of sexual dysfunction associated with hypertension and another condition
EP1426051B1 (en) * 2001-09-11 2008-07-16 Asahi Kasei Pharma Corporation Medicinal composition for prevention of or treatment for cerebrovascular disorder
US7019010B2 (en) * 2001-09-27 2006-03-28 Novertis Ag Combinations
ES2369216T3 (es) * 2002-05-17 2011-11-28 Novartis Pharma Ag Composición farmacéutica que comprende un inhibidor de renina, un bloqueador del canal de calcio y un diurético.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457132A (en) * 1989-03-22 1995-10-10 Peter K. T. Pang Kit used in the treatment for hypertension using combination therapy involving exogenous calcium and calcium channel blockers
US5178877A (en) * 1991-01-04 1993-01-12 Abbott Laboratories Encapsulated renin inhibitor composition
US5292741A (en) * 1992-08-18 1994-03-08 Merck & Co., Inc. Macrocycles incorporating quinazolinones
HU9700588D0 (en) * 1996-03-13 1997-05-28 Pfizer Method for improving morbidity and/or mortality

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Reams G.P. et al. Amiodipin therapy corrects renal abnormalities encountered in the hypertensive state, Am J Kidney Dis, 1987 Dec; 10(6): 446-51. *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2372079C1 (ru) * 2008-05-20 2009-11-10 Илья Николаевич Медведев Способ коррекции уровня микровезикул в крови при артериальной гипертонии, дислипидемии и нарушении толерантности к глюкозе
RU2373932C1 (ru) * 2008-05-20 2009-11-27 Илья Николаевич Медведев Способ коррекции уровня микровезикул в крови при артериальной гипертонии
US8613949B2 (en) 2008-09-22 2013-12-24 Novartis Ag Galenical formulations of organic compounds
RU2382644C1 (ru) * 2008-11-05 2010-02-27 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" Способ коррекции гипертрофии левого желудочка у больных ибс в сочетании с гипертонической болезнью

Also Published As

Publication number Publication date
US8183295B2 (en) 2012-05-22
AU2003240669A1 (en) 2003-12-02
CA2485081C (en) 2013-01-08
PT1507558E (pt) 2011-11-23
MXPA04011383A (es) 2005-02-14
ATE520417T1 (de) 2011-09-15
LU92000I2 (fr) 2012-07-16
US20050182042A1 (en) 2005-08-18
ES2369216T3 (es) 2011-11-28
RU2004137104A (ru) 2005-09-10
NO334382B1 (no) 2014-02-24
PL219032B1 (pl) 2015-03-31
BR0310084A (pt) 2005-02-15
US20080300238A1 (en) 2008-12-04
ECSP045428A (es) 2005-01-03
PL372203A1 (en) 2005-07-11
EP1507558B8 (en) 2012-02-15
IL164837A0 (en) 2005-12-18
EP2316488A1 (en) 2011-05-04
IL164837A (en) 2013-12-31
DK1507558T3 (da) 2011-12-05
US20120071470A1 (en) 2012-03-22
AU2003240669B2 (en) 2007-03-08
NZ536555A (en) 2007-03-30
NO20045459L (no) 2004-12-15
JP2010280708A (ja) 2010-12-16
JP5288678B2 (ja) 2013-09-11
CA2485081A1 (en) 2003-11-27
KR20050008717A (ko) 2005-01-21
KR20130109244A (ko) 2013-10-07
HK1074774A1 (en) 2005-11-25
CY2012011I2 (el) 2015-11-04
WO2003097098A1 (en) 2003-11-27
EP1507558A1 (en) 2005-02-23
ZA200408442B (en) 2006-02-22
CY1112013T1 (el) 2015-11-04
CY2012011I1 (el) 2015-11-04
KR20100137026A (ko) 2010-12-29
SI1507558T1 (sl) 2011-12-30
CN1655819A (zh) 2005-08-17
EP1507558B1 (en) 2011-08-17
JP2005526850A (ja) 2005-09-08

Similar Documents

Publication Publication Date Title
RU2316318C2 (ru) Фармацевтическая композиция, включающая ингибитор ренина, блокатор кальциевых каналов и диуретик
US8101659B2 (en) Methods of treatment and pharmaceutical composition
EP1467728B1 (en) Pharmaceutical compositions comprising valsartan and nep inhibitors
WO2007106708A2 (en) Combinations of the angiotensin ii antagonist valsartan and the nep inhibitor daglutril
HK1074774B (en) Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
HK1156212A (en) Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
MX2007009663A (en) Combination of organic compounds

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20140517